Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Nov 7;11(11):2095-2096.
doi: 10.2215/CJN.09470916. Epub 2016 Oct 25.

Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Verdict 2

Charles A Herzog  1
Affiliations
Comment

Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Verdict 2

Charles A Herzog. Clin J Am Soc Nephrol. .
No abstract available

Keywords: Anticoagulants; Atrial fibrillation; Blood Coagulation; Disease Management; Humans; Kidney Failure, Chronic; end-stage renal disease.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Relative risk reductions in stroke or systemic embolism and major hemorrhage by novel oral anticoagulants versus warfarin in patients with moderate CKD. Patients with CKD had estimated creatinine clearances of 30–49 ml/min, except for those treated with apixaban (25–50 ml/min). Risk reductions were statistically significant for dabigatran (150 mg) on stroke and apixaban on major hemorrhage. Reprinted from reference , with permission.
Figure 2.
Figure 2.
Hazard ratios (HRs) for subgroups of patients with CKD stage 3 from two randomized trials comparing anticoagulation with aspirin. For warfarin comparison from the SPAF III Study, the outcome was ischemic stroke and systemic embolism, and the aspirin group additionally received low ineffective doses of warfarin. For apixaban, the outcome was stroke and systemic embolism. 95% CI, 95% confidence interval; INR, international normalized ratio SPAF III, Stroke Prevention in Atrial Fibrillation. Reprinted from reference , with permission.
See this image and copyright information in PMC

Comment on

References

    1. McCullough PA, Ball T, Cox KM, Assar MD: Use of oral anticoagulation in the management of atrial fibrillation in patients with ESRD: Pro. Clin J Am Soc Nephrol 11: 2079–2084, 2016 - PMC - PubMed
    1. Keskar V, Sood MM: Use of oral anticoagulation in the management of atrial fibrillation in patients with ESRD: Con. Clin J Am Soc Nephrol 11: 2085–2092, 2016 - PMC - PubMed
    1. K/DOQI Workgroup : K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45[Suppl 3]: S1–S153, 2005 - PubMed
    1. Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E: Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 80: 572–586, 2011 - PubMed
    1. Qamar A, Bhatt DL: Stroke prevention in atrial fibrillation in patients with chronic kidney disease. Circulation 133: 1512–1515, 2016 - PubMed

Publication types